# wet age-related macular degeneration FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/wet-age-related-macular-degeneration

> No upcoming FDA catalysts in wet age-related macular degeneration; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2026 | [Eylea® (eylea) FDA approval](https://sec-api.dev/pdufa/eylea) | REGN | wet age-related macular degeneration | completed, approved | "•In April 2026, the FDA approved the extension of dosing intervals for EYLEA HD up to every 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following one year of successful response based on visual and anatomic outcomes." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm)) |
| September 2, 2026 | [Tarcocimab tedromer primary completion](https://sec-api.dev/pdufa/tarcocimab-tedromer) | KOD | Wet Age-related Macular Degeneration | completed | "NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-02 (ACTUAL); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06556368)) |
| Sep to Dec 2026 | [Tarcocimab tedromer topline data readout](https://sec-api.dev/pdufa/tarcocimab-tedromer) | KOD | Wet Age-related Macular Degeneration | scheduled | "NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-02 (ACTUAL); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06556368)) |

## Drugs

- [Eylea® (eylea)](https://sec-api.dev/pdufa/eylea) (REGN)
- [Tarcocimab tedromer](https://sec-api.dev/pdufa/tarcocimab-tedromer) (KOD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/wet-age-related-macular-degeneration.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "wet age-related macular degeneration FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/wet-age-related-macular-degeneration

```bibtex
@misc{secapidev_indications_wet_age_related_macular_degeneration_20261116,
  title        = {wet age-related macular degeneration FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/wet-age-related-macular-degeneration}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_wet_age_related_macular_degeneration_20261116","title":"wet age-related macular degeneration FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/wet-age-related-macular-degeneration","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
